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Methods: Plasma DES/CHO of AD patients and age-matched controls in a Japanese cross-sectional
cohort was determined. Plasma DES/CHO at baseline and follow-up visits was assessed in relation to
cognitive decline in Japanese and Swedish longitudinal cohorts.
Results: Plasma DES/CHO was significantly reduced in Japanese AD patients and significantly
correlated with Mini-Mental State Examination (MMSE) score. The longitudinal analysis revealed
that plasma DES/CHO in AD patients shows a significant decrease at follow-up intervals. The decline
in plasma DES/CHO is larger in the AD group with rapid progression than in that with slow progres-
sion. The changes in plasma DES/CHO significantly correlated with changes in the MMSE score.
Conclusion: Plasma DES/CHO is decreased in AD patients and may serve as a longitudinal surro-
gate marker associated with cognitive decline.
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Alzheimer’s disease (AD) is one of the most common and
debilitating neurodegenerative disorders of the aging popula-
tion. AD manifests itself as a progressive decline in memory
accompanied by other cognitive and functional disabilities
[1]. From the viewpoint of clinical practice and therapeutic
clinical trials in AD, biomarkers are becoming increasingly
important particularly when disease-modifying drugs will
become available. Numerous studies have shown that tau,
phosphorylated tau, and amyloid-b (Ab) 42 in cerebrospinaluthor. Tel.: 181-25-227-2343; Fax: 181-25-227-
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licenses/by-nc-nd/4.0/).fluid (CSF) are reliable biomarkers for AD diagnosis [2–4].
However, the CSF examination of AD patients has not been
broadly applied in general clinical practice because lumbar
puncture to obtain CSF is relatively invasive and time
consuming. Moreover, these CSF markers do not seem to
be associated with longitudinal cognitive decline in
patients with AD [5]. Thus, there is a compelling need to
establish a noninvasive biomarker for AD that follows the
disease progression. Efforts to find reliable blood-based bio-
markers for AD have met with little success [6]. Several re-
ports have been published describing altered levels of
proteins, peptides, or metabolites in patients with AD, but
those blood-based biomarkers have proven difficult to repli-
cate in independent studies [6], highlighting the importance
of multiple validations.his is an open access article under the CC BY-NC-ND license (http://
Table 1
Demographic characteristics of AD patients and age-matched cognitively
normal controls in the Japanese cross-sectional cohort
Variable Control (n 5 201) AD (n 5 200)
Female (%) 72 75
Age, mean (SD)
Age at examination (y) 77.6 (4.7) 77.6 (5.4)
Age at onset (y) n/a 73.5 (5.0)
MMSE, mean (SD) 28.7 (1.5) 17.0 (5.2)**
APOE genotype
2*3 15 6
2*4 2 1
3*3 151 71
3*4 32 99
4*4 1 23
DES/CHO (1026), mean (SD) 456 (119) 357 (134)**
Abbreviations: AD, Alzheimer’s disease; n/a, not available; MMSE,
Mini-Mental State Examination; DES/CHO, desmosterol-to-cholesterol
ratio.
**P , .01.
Y. Sato et al. / Alzheimer’s & Dementia: Diagnosis, Assessment & Disease Monitoring 1 (2015) 67–7468In our previous report, we found that the plasma
desmosterol-to-cholesterol ratio (DES/CHO) is significantly
decreased in Caucasian patients with AD and subjects with
mild cognitive impairment (MCI) [7]. Desmosterol is the
most abundant precursor but rarely exceeds 1% of total brain
sterols because the conversion from desmosterol to choles-
terol is tightly regulated by the enzyme 3-hydroxysterol
24-reductase (DHCR24) [8]. A substantially higher desmos-
terol concentration in the hippocampus could be attributed to
neurogenesis and synaptic plasticity that take place in the
adult dentate gyrus [9]. Conversely, a decrease in desmos-
terol level in the hippocampus could at least in part correlate
with the reduced number of progenitor cells differentiating
into neurons [10]. These reports suggest an important role
of desmosterol in the brain.
With this background, we here measured plasma DES/
CHO of samples from a large Japanese cohort to extend
our previous result that plasmaDES/CHO is decreased in pa-
tients with AD in a different ethnic group. Furthermore, weTable 2
Demographic characteristics of subjects in the longitudinal study
Variable
Japanese cohort,
AD (n 5 17) Control (n 5 6)
Female (%) 71 75
Age, mean (SD) 68 (8) 67 (9)
Follow-up time, y, mean (SD) 2.0 (1.0) 2.7 (0.8)
MMSE, mean (SD)
Baseline 20 (5) 30 (1)
Follow-up 16 (7) 30 (0)
DMMSE 24 (4)** 0 (1)
DES/CHO (1026), mean (SD)
Baseline 329 (103) 654 (146)
Follow-up 290 (79) 661 (130)
% Change 210 (14)* 1.7 (5.1)
Abbreviations: AD, Alzheimer’s disease; MCI, mild cognitive impairment; MM
ratio.
*P , .05, **P , .01.performed longitudinal studies to determine the association
between plasma DES/CHO and cognitive decline in patients
with AD over time.2. Materials and methods
2.1. Subjects
For cross-sectional analysis, plasma samples of 200 pa-
tients with AD and 201 age-matched cognitively normal
elderly individuals (older than 65 years) were collected
from seven clinical institutions in Japan (Table 1). The diag-
nosis of AD was made on the basis of the criteria of the Na-
tional Institute of Neurological and Communicative
Diseases and the Stroke–Alzheimer’s Disease and Related
Disorders Association [11]. Each participant was asked to
complete the Mini-Mental State Examination (MMSE)
[12]. APOE genotyping was performed as previously re-
ported [13].
For longitudinal analysis, we used 17 subjects with AD
(Japanese longitudinal cohort collected at Niigata University
Hospital) and 28 subjects (Swedish longitudinal cohort con-
sisting of 6 control, 12 MCI, and 10 AD subjects collected at
Uppsala University Hospital), whose blood was drawn at
two different time points (Table 2). Additional longitudinal
plasma samples of 30 subjects at least at 3 different time
points were obtained from Uppsala University Hospital
(AD, n 5 6; MCI, n 5 6; control, n 5 2) or purchased
from PrecisionMed, Inc. (AD, n 5 12; control, n 5 4)
(San Diego, CA, USA). The criteria of Petersen et al.
[14,15] were used for the diagnosis of MCI. To be
considered as having MCI, the patients had to be free of
significant underlying medical, neurologic, or psychiatric
illness and meet the following criteria: (1) subjective
memory complaint, (2) objective signs of decline in any
cognitive domain, (3) intact activities of daily living, and
(4) clinical features not fulfilling the DSM-IV/ICD-10
criteria for dementia [16]. The two AD/MCI groups with
slow and rapid progression were classified on the basis ofSwedish cohort
Combined cohort,
MCI/AD (n 5 39)MCI (n 5 12) AD (n 5 10)
33 30 56
62 (8) 66 (10) 66 (9)
1.8 (0.9) 2.2 (0.9) 2.1 (1.0)
28 (2) 25 (3) 24 (6)
28 (2) 22 (3) 21 (7)
0 (2) 23 (3)* 22 (4)**
660 (200) 556 (232) 489 (225)
607 (237) 487 (276) 438 (237)
28.3 (21) 218 (27) 211 (20)**
SE, Mini-Mental State Examination; DES/CHO, desmosterol-to-cholesterol
Fig. 1. Decreased plasmaDES/CHO in patients with AD. (A) Comparison of plasma desmosterol-to-cholesterol ratio (DES/CHO) between 201 control and 200
AD subjects from a large Japanese cohort. (B) Comparison of plasma DES/CHO among male control (M_Cont), female control (F_Cont), male AD (M_AD),
and female AD (F_AD) subjects. (C) Comparison of plasmaDES/CHObetween control subjects withoutAPOE ε4 (nonE4_Cont) and withAPOE ε4 (E4_Cont),
and AD patients without APOE ε4 (nonE4_AD) and with APOE ε4 (E4_AD). (D) Comparison of plasma DES/CHO among groups classified as MMSE groups.
*P , .05; **P , .01.
Y. Sato et al. / Alzheimer’s & Dementia: Diagnosis, Assessment & Disease Monitoring 1 (2015) 67–74 69the mean change in MMSE score (change from the baseline)
as threshold. Written informed consent was obtained from
each of the participants (or the respective legal guardian);
the study was approved by the appropriate university, hospi-
tal, and company institutional ethics committees.
2.2. Blood sampling and laboratory measurement
Peripheral blood samples were obtained from each partic-
ipant using the commercially available blood collection
tubes (Terumo Venoject for Japanese cohort and BD Vacu-
tainer for Swedish cohort) containing EDTA as the anticoag-
ulant. Plasma was separated by centrifugation at 1500 g for
15 minutes at room temperature before being aliquoted and
stored at 280C until analysis.
The concentrations of desmosterol and cholesterol were
measured with a liquid chromatography mass spectrometer
(LC/MS), as described previously [7]. Briefly, 25 mL of
plasma was spiked with cholesterol-25,26,26,26,27,27,27-
D7 and desmosterol-26,26,26,27,27,27-D6 as internal stan-
dards. Fifty percent potassium hydroxide was then added
to the solution, which was then mixed thoroughly and incu-bated at 70C for 60 minutes. After the incubation, 2 mL of
hexane and 0.5 mL of phosphate-buffered saline (pH 6.8)
were added and mixed well. The solution was centrifuged
for 10 minutes at 2000 g, and the upper organic phase was
transferred to a new tube. The lower layer was extracted
with an additional 1 mL of hexane, which was also added
to the organic-phase extract. The solvents were evaporated
to dryness under a nitrogen gas stream at 40C, and the ob-
tained pellet was reconstituted in ethanol and the resulting
solution was subjected to liquid chromatography/atomo-
spheric pressure chemical ionization-mass spectrometer
analysis as described previously [7].
2.3. Statistical analysis
Values are shown as mean6 standard deviation. Correla-
tions between different variables were assessed using the
Pearson correlation coefficient on log-transformed data.
The t test or analysis of variance was carried out to determine
differences between two or more groups. Nonparametric
tests (Mann-Whitney U test) were carried out when the vari-
ables were not normally distributed. The paired t test was
Fig. 2. Change in plasma DES/CHO between baseline and follow-up visits. AD/MCI subjects were classified into two groups, namely, those with slow pro-
gression (A, D, G) and those with rapid progression (B, E, H) on the basis of the mean DMMSE between baseline and follow-up visits in a Japanese cohort
(A–C), a Swedish cohort (D–F), and a combined cohort (G–I). Plasma DES/CHO remains stable in the group with slow progression (A, D, G), whereas in
the group with rapid progression, a significant decline over time was found (B, E, H). The change in plasma DES/CHO was significantly larger in the group
with rapid progression than in the group with slow progression (C, F, I). *P , .05; **P , .01.
Y. Sato et al. / Alzheimer’s & Dementia: Diagnosis, Assessment & Disease Monitoring 1 (2015) 67–7470carried out to see the difference in the individual values be-
tween baseline and follow-up visits. The statistical signifi-
cance was set at P , .05.
3. Results
3.1. Cross-sectional study of plasma desmosterol
The characteristics of the AD and age-matched control
subjects included in this cross-sectional study are listed in
Table 1. A significant decline in plasma DES/CHO was
observed in patients with AD compared with control sub-
jects (P , .01; Fig. 1A). The decline in plasma DES/CHO
in AD patients was significant regardless of gender or
APOE ε4 status (Fig. 1B and C). There was a significant
decline in plasma DES/CHO in AD patients with both the
APOE ε3/3 and ε3/4 genotypes (data not shown; see
Supplementary Fig. 1A and B for review). Plasma DES/CHO of female subjects in both the AD and control groups
was significantly lower than that of male subjects (Fig. 1B,
P , .01). No significant correlation of plasma DES/CHO
with age was observed (data not shown). A significant corre-
lation between plasma DES/CHO and MMSE score in both
males and females was observed (data not shown; see
Supplementary Fig. 1C and D). We divided subjects of this
cohort into four MMSE score groups: high MMSE score
(30 S MMSE S 26), middle MMSE score (25 S MMSE
S 20), low MMSE score (19 S MMSE S 10), and very
low MMSE score (9 S MMSE S 0). We then compared
DES/CHO among these groups. A significant difference be-
tween the high MMSE score group and the other MMSE
score groups was observed (Fig. 1D). The linear trend anal-
ysis revealed that there was also a significant change
showing that groups with lower MMSE scores had lower
DES/CHO (trend t test: P , .01).
Fig. 3. Comparison of longitudinal change in plasma DES/CHO between control and AD subjects. (A) Longitudinal changes in plasma DES/CHO at two
different points were compared between control subjects and AD patients from the combined cohort. *P , .05. (B) Longitudinal changes in plasma DES/
CHO at multiple points were compared between control subjects and AD patients from the Swedish cohort and a commercially available resource. **P, .01.
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Longitudinal plasma samples were collected from two
clinical institutes, namely, Niigata University Hospital (Jap-
anese cohort) and Uppsala University Hospital Memory
Clinic (Swedish cohort). Forty-seven participants composed
of 17 subjects in the Japanese cohort and 30 subjects in the
Swedish cohort were included, and the demographic charac-
teristics of these subjects are listed in Table 2. At baseline,
DES/CHO in Japanese AD patients was significantly lower
than that of Swedish AD patients (P , .01).
In the Japanese longitudinal cohort, the average change in
the MMSE score (DMMSE) between the baseline and
follow-up visits was 24 6 4 with a change in DES/CHOFig. 4. Correlation between longitudinal changes in MMSE and plasma
DES/CHO (%) in AD patients, MCI patients, and normal subjects. There
were 122 points for blood collection, consisting of 30 baselines and 92
follow-ups (AD, 52 follow-ups; MCI, 13 follow-ups; and control, 27
follow-ups). There was a significant correlation between changes in
MMSE and plasma DES/CHO (r 5 0.37, P , .01).of 210 6 14% (Table 2). Both MMSE score and plasma
DES/CHO significantly decreased between the two visits
in the Japanese cohort (paired t test, P, .05). In the Swedish
cohort, the MMSE score (236 3) decreased significantly in
AD patients between the baseline and follow-up visits
(P , .05). However, in this cohort, there was no significant
change in DES/CHO in both the AD patients and MCI sub-
jects (Table 2). In the combined AD/MCI cohort, MMSE
score (22 6 4) and plasma DES/CHO (211 6 20%)
decreased significantly between the two visits (Table 2).
Next, we divided the AD/MCI subjects into two groups,
namely, those with slow or rapid progression, on the basis
of their mean DMMSE in the Japanese (cutoff score, 24)
and Swedish cohorts (cutoff score, 22) and compared the
longitudinal change in plasma DES/CHO between groups
(Fig. 2). Although the AD/MCI group with slow progression
did not show any significant change in plasma DES/CHO
(Fig. 2A, D, and G), groups with rapid progression showed
a significant decrease in plasma DES/CHO between the
baseline and follow-up visits (Fig. 2B, E, and H). In addition,
the change in plasma DES/CHO was significantly larger in
the AD/MCI group with rapid progression than in the group
with slow progression in the Japanese, Swedish, and com-
bined cohorts (Fig. 2C, F, and I).
We further compared the longitudinal change in plasma
DES/CHO in control subjects and AD patients (Fig. 3).
The change in DES/CHO between the two visits was
212.8 6 19.7 in the AD patients, which was significantly
larger than that in the control subjects (1.7 6 5.3;
Fig. 3A). These results suggest that although plasma DES/
CHO in normal subjects remained stable, plasma DES/
CHO in AD patients tended to decline over time.
Finally, we performed another longitudinal study to
determine the association between plasma DES/CHO and
DMMSE in 30 participants, including 18 AD, 6 MCI, and
6 control subjects from either the Swedish cohort or from
PrecisionMed. Blood samples were collected every year or
Y. Sato et al. / Alzheimer’s & Dementia: Diagnosis, Assessment & Disease Monitoring 1 (2015) 67–7472every 6 months from the participants. There were 122 points
for blood collection, consisting of 30 baselines and 92
follow-ups. The correlation between the DMMSE and the
change in plasma DES/CHO (compared with baseline)
determined using all 92 follow-up points is shown in
Fig. 4. There was a significant correlation between the lon-
gitudinal DMMSE and the change in DES/CHO from the
baseline (P5 .01, r5 0.37). All the changes in MMSE score
and plasma DES/CHO in each of the participants are shown
(see Supplementary Fig. 2). In addition, AD patients showed
a significant decrease in plasma DES/CHO at follow-up in-
tervals (27.7 6 36.8%) compared with the control subjects
(6.4 6 12.3%) in this cohort (Fig. 3B).4. Discussion
The present cross-sectional study using a Japanese cohort
was undertaken to replicate our previous finding that plasma
DES/CHO is decreased in Caucasian patients with AD. The
following points were confirmed in the present Japanese and
previously reported Caucasian cross-sectional cohorts: (1)
plasma DES/CHO was decreased in patients with AD in
comparison with control subjects, (2) the decrease in plasma
DES/CHO in AD patients was independent of gender and
APOE genotype, (3) female subjects tended to have a lower
plasma DES/CHO than male subjects, and (4) plasma DES/
CHO correlated significantly with the MMSE score. Taken
together, the results suggest that plasma DES/CHO may be
a potential diagnostic biomarker reflecting cognitive
dysfunction in AD patients.
Recently, Popp et al. [17] have reported that the plasma
desmosterol level does not change in AD patients. The
discrepancy in finding between that and the present study
may be explained by differences in the analytical methods
used to determine the concentration of desmosterol. We pre-
viously showed that the LC/MS method that we used in the
present study enables the purification of desmosterol in
plasma more efficiently than the gas chromatography
method used in the study by Popp et al. [7,17]. Thus, the
LC/MS method is likely to be more suitable for the
measurement of plasma desmosterol concentration.
Here, we determined for the first time the longitudinal
change in plasma DES/CHO and examined a possible asso-
ciation with concurrent cognitive decline in AD/MCI pa-
tients. Our results revealed (1) that plasma DES/CHO was
relatively stable over time in cognitively normal controls,
whereas it significantly decreased in AD patients; (2) a
more pronounced decline in plasma DES/CHO in the AD/
MCI group with rapid progression than in the group with
slow progression; and (3) that the longitudinal change in
plasma DES/CHO positively correlated with the change in
the MMSE score. These results suggest that the plasma
DES/CHO change is associated with the cognitive decline
in AD and might be used to monitor the progression of
cognitive decline in patients with AD. It will be interesting
to clarify the usefulness of monitoring plasma DES/CHOas a surrogate marker for evaluating the effects of clinical
drug trials in patients with AD.
Our longitudinal study suggests that the plasmaDES/CHO
changes before the appearance of clinical symptoms, as deter-
mined byMMSE in some cases (see Supplementary Fig. 2 for
review; subjects A, C, and H). The result obtained from the
subject with MCI that converted to AD (see Supplementary
Fig. 2 for review; subject S) may suggest that plasma DES/
CHO is useful as a progressionmarker to monitor the conver-
sion from MCI to AD. In this connection, recent lipidomic
analysis showed that the quantification of several lipidmetab-
olites in plasma, such as phosphatidylcholine and acylcarni-
tine, is useful for predicting phenoconversion to amnestic
MCI or AD in cognitively normal subjects [18].
There is now accumulating evidence that cholesterol
metabolism may be relevant to the production and clearance
of Ab and thus to the Ab-related toxicity in the pathogenesis
of AD [19]. The strongest genetic risk factor for sporadic AD
is the ε4 allele of APOE, which encodes apolipoprotein E
(apoE), with a crucial role in cholesterol metabolism [20].
The presence of APOE ε4 may contribute to the pathologic
accumulation and deposition of cerebral Ab at early preclin-
ical disease stages [21]. A recent study has shown that CSF
apoE levels are decreased in patients with AD and that MCI
in subjects with a low CSF apoE level will more likely
convert to AD [22]. An interaction between APOE genotype
and plasma desmosterol level may be postulated because
desmosterol is the immediate precursor of cholesterol. How-
ever, the plasma desmosterol level was not clearly associated
with APOE genotype in this study.
It is of particular interest that the level of desmosterol in
the AD brain was found to be lower than that of control brain
[7,23]. It has been demonstrated that the levels of steroid
hormones (e.g., progesterone, pregnenolone, and 17aOH-
progesterone) that exhibit inhibitory activity against
DHCR24 are decreased in the AD brain, particularly in the
vicinity of plaques and neurofibrillary tangles [24]. Notably,
the concentration of desmosterol is 100-fold higher in the rat
brain than in the rat liver [25], which implies that most of the
desmosterol in the blood might originate from the brain.
Taken together, it could be speculated that brain desmosterol
level may decrease with an increase in DHCR24 activity in
the AD brain; this may subsequently result in a change in
plasma DES/CHO. The question of why plasma DES/CHO
decreases in patients with AD and is associated with longi-
tudinal cognitive decline in the course of the disease war-
rants further investigation.
Although our findings, using samples from cross-sectional
and longitudinal cohorts, are interesting, our study has some
limitations. We did not analyze the samples from other types
of dementia, including dementia with Lewy bodies, fronto-
temporal dementia, and vascular dementia. An additional
cross-sectional study that includes samples from other types
of dementia will be necessary. The number of samples from
longitudinal cohorts in this study is relatively small. Longitu-
dinal studies with a prospective design using a larger number
Y. Sato et al. / Alzheimer’s & Dementia: Diagnosis, Assessment & Disease Monitoring 1 (2015) 67–74 73of samples should be performed to confirm the utility of
plasma DES/CHO as a longitudinal biomarker. Moreover, it
is important to understand how early plasmaDES/CHO starts
to decline using longitudinal samples from asymptomaticAD
subjects with amyloid deposition confirmed by amyloid-
positron emission tomography imaging. Although our find-
ings need to be validated in independent cohorts, our data
suggest that the use of plasma desmosterol as a blood
biomarker can be useful in the diagnosis of AD and also in
monitoring disease progression.
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1. Systemic review: There is a compelling need to
establish blood-based biomarker to diagnose Alz-
heimer’s disease (AD) and monitor the disease pro-
gression. A previous study reported that plasma
desmosterol-to-cholesterol ratio (DES/CHO) is
significantly decreased in Caucasian patients
with AD.
2. Interpretation: We found that plasma DES/CHO was
significantly reduced in Japanese AD patients. The
longitudinal study revealed (1) that plasma DES/
CHO was relatively stable in normal controls,
whereas it significantly decreased in AD patients;
(2) a more pronounced decline in plasma DES/
CHO in the AD/MCI group with rapid progression
than in that with slow progression; and (3) that the
longitudinal change in plasma DES/CHO positively
correlated with the change in MMSE score.
3. Future directions: A future cross-sectional study that
includes samples from other types of dementia and
longitudinal studies with a prospective design using a
larger number of samples need to be performed to
confirm the utility of plasma DES/CHO.References
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